Stock TSVT 2SEVENTY BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings 2seventy bio, Inc.

Equities

TSVT

US9013841070

Real-time Estimate Cboe BZX
Other stock markets
 03:41:34 2024-06-12 pm EDT 		5-day change 1st Jan Change
4.19 USD +6.62% Intraday chart for 2seventy bio, Inc. -7.24% -0.94%
Jun. 10 Transcript : 2seventy bio, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 01:20 PM
Jun. 06 Top Midday Decliners MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
2SEVENTY BIO, INC. Stock 2seventy bio, Inc.
-0.94% 202M -
MODERNA, INC. Stock Moderna, Inc.
+47.77% 56.87B
B-
LONZA GROUP AG Stock Lonza Group AG
+37.15% 39.72B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-6.04% 39.27B
B
CELLTRION, INC. Stock Celltrion, Inc.
-6.90% 28.73B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.68% 26.21B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-16.12% 19.79B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.43% 12.28B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+28.21% 12.23B
B+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.10% 12.12B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TSVT Stock
  4. Ratings 2seventy bio, Inc.